PF-05089771 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inherited Erythromelalgia
Conditions
Inherited Erythromelalgia
Trial Timeline
Oct 22, 2012 → Jul 12, 2013
NCT ID
NCT01769274About PF-05089771 + Placebo
PF-05089771 + Placebo is a phase 2 stage product being developed by Pfizer for Inherited Erythromelalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT01769274. Target conditions include Inherited Erythromelalgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01772264 | Phase 1 | Completed |
| NCT01769274 | Phase 2 | Completed |
Competing Products
4 competing products in Inherited Erythromelalgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Umbilical cord blood transplantation with HSC835 | Novartis | Phase 1/2 | 41 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| BIIB074 + Placebo | Biogen | Phase 2 | 49 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |